PARP Inhibitors and Haematological Malignancies—Friend or Foe?
Since their introduction several years ago, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have become the standard of care for breast and gynaecological cancers with <i>BRCA</i> gene mutations. Given that PARPi act by exploiting defective DNA repair mechanisms within tumour cell...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/618911a1190e402aa4b388aa486c5418 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|